All In Biotech

Drug Trial Radar · NCT01747174

REperfusion Facilitated by LOcal Adjunctive Therapy in ST-elevation Myocardial Infarction

Randomized Controlled Trial Comparing Intracoronary Administration of Adenosine or Sodium Nitroprusside to Control for Attenuation of Microvascular Obstruction During Primary Percutaneous Coronary Intervention

Last checked: Nov 20, 2026Latest source record: Jun 16, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 247 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

247

Actual

Start

Oct 2011

Primary completion

Oct 2014

Study completion Dec 2014

Sponsor

Lead sponsor
University Hospitals, LeicesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether intra-coronary adenosine or sodium nitroprusside (SNP) delivered selectively via a thrombus aspiration catheter (or if unsuccessful via a coronary microcatheter) following thrombus aspiration in Primary Percutaneous Coronary Intervention (P-PCI) reduces microvascular obstruction (MVO) parameters and infarct size as measured with cardiac MRI, compared with standard treatment following thrombus aspiration in patients presenting with ST-elevation myocardial infarction (STEMI).

Conditions

  • ST-elevation Myocardial Infarction (STEMI)

Interventions

  • IC AdenosineDrug

    IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.

  • IC Sodium nitroprusside (SNP)Drug

    IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.

  • Standard PCIProcedure

    PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CMR measured infarct size (% LV mass)Time frame: 48-72 hours post procedure

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Glenfield Hospital

    Leicester, Leicestershire, United Kingdom

  • Freeman Hospital

    Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • University Hospital

    Coventry, West Midlands, United Kingdom

  • Leeds General Infirmary

    Leeds, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.